In colorectal cancer models, which share similar pathological environments and treatment approaches with gastric cancer, FGFR4 silencing has been shown to induce poly ADP-ribose polymerase-1 (PARP) cleavage. The gene discussed is PARP1; the disease is colorectal cancer.